Kaleo, Inc.

Kaléo is a pharmaceutical company specializing in drug-device combinations, particularly innovative auto-injector systems. Founded by twin brothers Eric and Evan Edwards and based in Glen Allen, Virginia, Kaléo designs and manufactures auto-injectors for urgent medical conditions with an emphasis on patient safety, ease of use, and reliability. The company's proprietary Aerio™ platform leverages Human Factors Engineering and fully automated manufacturing to deliver precision drug-delivery devices adaptable across multiple disease categories and environments. Kaléo's marketed portfolio includes AUVI-Q® (epinephrine auto-injector for severe allergies), naloxone auto-injectors for opioid overdose response, and medical countermeasures for nerve agent exposure and chemical threats. The company partners with pharmaceutical manufacturers and government agencies to develop custom drug-delivery solutions and maintains a strong commitment to patient access through financial assistance programs. With approximately 155 issued or pending patents, Kaléo serves both civilian healthcare markets and specialty applications including emergency medicine and global health security.